To clarify the most useful long-term glycemic control marker in chronic liver disease, we simultaneously evaluated daily profiles of blood glucose (BG), various liver function tests and four long-term glycemic control markers {hemoglobin Aic (HbA1c), fructosamine (FRA), glycated albumin (GA) and 1, 5-anhydroglucitol (1, 5-AG)} in 85 inpatients with chronic liver diseases who had been maintained in stable condition for at least two weeks. There were strong significant correlations between average BG calculated from daily BG profiles and all four markers (r=0.60-0.83). Evaluation in normal BG (both 110 mg/d
lfor preprandial levels and 160 mg/d
lfor postprandial levels) and high BG (200 mg/d
lfor postprandial levels) groups revealed that HbAic and 1, 5-AG were shifted toward lower levels while FRA and GA were shifted toward higher levels, with these deviations accounting for 21-24% of the abnormal values observed. In examination of the normal BG group alone, the hepaplastin test (HPT) revealed the most significant correlations with each of the glycemic control markers (HbA1c: r=0.49; GA:-0.68; FRA:-0.59; 1, 5-AG: 0.42.) From these results, we derived corrected values for all of these markers by employing HPT. Among these values, the corrected GA (=GA+0.124×HPT-12.4) exhibited the strongest correlation with the average BG (r=0.85) and the minimal rate of abnormal values (12%). Thus, corrected GA has the potential to serve as a readily available glycemic control marker for patients with chronic liver disease.
View full abstract